Compare Hims and Hers Health Inc (HIMS) vs Modine Manufacturing Company (MOD) Price & Performance

Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.

The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.

Modine Manufacturing (MOD) trades at $182.00, down 3.93% on the day, amid a bearish technical signal and recent volatility following the completion of its Performance Technologies spin-off and merger with Gentherm. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.53 surpassing the $1.30 expectation. Analyst sentiment remains strongly positive with a consensus price target of $331.25, though technical indicators show selling pressure with key support at $177 and resistance at $187.

The outlook is mixed; strong analyst support and recent strategic moves like the spin-off suggest long-term growth potential, but near-term risks include integration challenges, a high P/E ratio of 67.87, and a projected decline in net profit margin for 2026. Investors should weigh solid fundamentals against current technical weakness and execution risks.